A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.

Systems and methods for treating drug resistant pneumonia and tuberculosis using hypochlorous acid (HOCl) are disclosed. Embodiments of the present disclosure relate to nebulizing HOCl as a method of treating drug resistant bacteria, in particular, bacterial pneumonia pathogens (i.e., Streptococcus pneumoniae) and Mycobacterium tuberculosis bacteria. The nebulized HOCl solution may be approximately 180 parts per million (PPM) of the aqueous solution and have a pH of less than 6.

The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor β-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.

Methods for the treatment of pulmonary cancers (primary, secondary, metastatic, etc.) using an electronic breath actuated droplet delivery device to deliver a cancer therapeutic directly to the pulmonary system of a subject in need thereof is disclosed. An in-line droplet delivery device and related methods for delivering precise and repeatable dosages to a subject for pulmonary use is disclosed. The in-line droplet delivery device includes a housing, an ejector mechanism, and at least one differential pressure sensor. The in-line droplet delivery device is automatically breath actuated by the user when the differential pressure sensor senses a predetermined pressure change within housing. The in-line droplet delivery device is then actuated to generate a plume of droplets having an average ejected particle diameter within the respirable size range, e.g, less than about 5-6 μm, so as to target the pulmonary system of the user.

The present disclosure provides methods for treating a subject having a coronavirus infection by administering a composition that includes a sACE2 polypeptide to the lungs of a subject infected with a coronavirus. The sACE2 polypeptide includes the extracellular portion of the human ACE2 polypeptide and acts as a decoy, binding the spike (S) protein of coronavirus and thereby preventing the interaction of the S protein with membrane-associated ACE2 expressed on pulmonary cells, thus disrupting the infection process. The sACE2 polypeptide is derived from human ACE2, preventing potential immune reactions of the subject to the therapeutic polypeptide. The sACE2 polypeptide is administered locally to the site of the pathology, avoiding potential adverse effects of systemic delivery.

The present disclosure relates to a method of treating or preventing a viral infection by raising the pH of the airways of a subject. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution. Additionally, the method provides co-administering an anti-viral composition to the subject.

The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of pulmonary hypertension, lung infections or acute or chronic lung injury, particularly lung fibrosis.

The present invention discloses a solution formulation for aerosol inhalation of naringenin and preparation method thereof. The formulation is prepared from 1 part by weight of naringenin, 15-30 parts by weight of hydroxypropyl β-cyclodextrin, a buffer-salt solution and an appropriate amount of an excipient. The preparation method includes: preparing a buffer-salt solution of a pH value of 7-8.5 by using the buffer salt, adding the naringenin into the buffer-salt solution, then adding the hydroxypropyl P-cyclodextrin, shaking in a constant-temperature air bath till complete dissolving and coating, adding an appropriate amount of the excipient, filtering, filling and sterilizing. The present invention, by firstly increasing the solubility of the free naringenin in the solvent by adjusting the pH value, and then coating the naringenin with the hydroxypropyl β-cyclodextrin, significantly increases the overall concentration of the naringenin in the solvent.

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.